Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Santhera Pharmaceuticals : to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone

10/06/2020 | 01:10am EST

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24, 4133 Pratteln, Switzerland

Phone: +41 61 906 89 50 | Fax: +41 61 906 89 51

www.santhera.com

Santhera will hold a conference call today at 13:00 CEST, 12:00 BST, 07:00 EDT. Details are at the end of this statement.

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone

Pratteln, Switzerland, October 6, 2020 - Santhera Pharmaceuticals (SIX: SANN) announces the discontinuation of its Phase 3 SIDEROS study with Puldysa® (idebenone) in patients with Duchenne muscular dystrophy (DMD) who are in respiratory decline and receive concomitant glucocorticoid treatment. Data from an interim analysis conducted by the independent Data and Safety Monitoring Board (DSMB) concluded that the study was unlikely to meet its primary endpoint. As a consequence, Santhera will discontinue the study, withdraw the European marketing authorization application and end the global development program for Puldysa. The Company intends to initiate a restructuring plan for the business with a focus on retaining key functions for bringing DMD drug candidate vamorolone to patients and execute on its other pipeline programs.

Based on the now completed interim analysis which tested for efficacy, the DSMB has recommended the SIDEROS study be discontinued due to futility. The interim analysis was based on the primary endpoint of the study, the change of forced vital capacity % predicted (FVC%p) from baseline to 18 months of treatment. The outcome revealed that the probability of reaching the primary endpoint at the end of the study is too small to merit the continuation of the study. There were no safety concerns noted by the DSMB.

Santhera will stop the SIDEROS trial (including extension) and participants who are enrolled in the study will discontinue study medication and complete the study's follow-up evaluations. Furthermore, following up on the recommendation from the DSMB, Santhera will discuss the impact of ending the SIDEROS study on ongoing expanded access programs with the corresponding regulatory bodies.

"We would like to thank the patients and the families, as well as investigators and medical professionals, who participated in the SIDEROS study. Without their contributions we would not be able to advance DMD research," said Dario Eklund, Chief Executive Officer of Santhera. "While this is obviously not the outcome we expected, all our efforts in DMD will now be focused on progressing the promising drug candidate vamorolone which we recently licensed from ReveraGen to its next inflection point, the readout of 6-month topline data from the pivotal VISION-DMD study planned for the second quarter of 2021."

In connection with this decision, Santhera intends to start a restructuring process, aligning its operations to focus on progressing vamorolone for DMD, lonodelestat for cystic fibrosis and other lung diseases and its discovery-stage gene therapy approach for congenital muscular dystrophy.

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone October 6, 2020 / Page 2 of 2

Conference Call

Santhera will host a conference call today at 13:00 CEST / 12:00 BST / 07:00 EDT. Dario Eklund, CEO of Santhera, will discuss this update. Participants are invited to call one of the following numbers 10-15 minutes before the conference call starts (no dial-in code is required):

Europe:

+41

58 310 50 00

UK:

+44

207 107 06 13

USA:

+1 631 570 56 13

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-classanti-inflammatory drug candidate with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensedex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com.

Puldysa® and Raxone® are trademarks of Santhera Pharmaceuticals.

For further information please contact: public-relations@santhera.comor

Eva Kalias, Head External Communications Phone: +41 79 875 27 80 eva.kalias@santhera.com

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Santhera Pharmaceuticals Holding AG published this content on 06 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 October 2020 05:09:05 UTC


© Publicnow 2020
All news about SANTHERA PHARMACEUTICALS HOLDING AG
11/26SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
PU
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25Santhera Completes Capital Increase for Financing Arrangements
GL
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
PU
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
PU
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
AQ
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
PU
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
AQ
More news
Financials
Sales 2020 14,6 M 16,4 M 16,4 M
Net income 2020 -55,3 M -61,8 M -61,8 M
Net Debt 2020 - - -
P/E ratio 2020 -0,90x
Yield 2020 -
Capitalization 53,9 M 60,2 M 60,3 M
Capi. / Sales 2020 3,69x
EV / Sales 2021 1,92x
Nbr of Employees 113
Free-Float 86,1%
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 3,00 CHF
Last Close Price 2,84 CHF
Spread / Highest target 5,63%
Spread / Average Target 5,63%
Spread / Lowest Target 5,63%
EPS Revisions
Managers
NameTitle
Dario Eklund Chief Executive Officer
Elmar J. Schnee Chairman
Andrew P. Smith Chief Financial Officer
Kristina Sjöblom Nygren Chief Medical Officer, EVP & Head-Development
Thomas Meier Director
Sector and Competitors